HYPEREOSINOPHILIC SYNDROME
Clinical trials for HYPEREOSINOPHILIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new HYPEREOSINOPHILIC SYNDROME trials appear
Sign up with your email to follow new studies for HYPEREOSINOPHILIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to tame rare blood disorder flares
Disease control OngoingThis Phase 3 study tests whether benralizumab, a biologic injection given every 4 weeks, can reduce flares in people with hypereosinophilic syndrome (HES), a rare condition where too many eosinophils cause organ damage. About 134 patients aged 12 and older will receive either ben…
Matched conditions: HYPEREOSINOPHILIC SYNDROME
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Cancer drug shows promise in taming rare blood disorder
Disease control OngoingThis study tests whether the drug imatinib (Gleevec) can safely lower high levels of eosinophils (a type of white blood cell) in people with hypereosinophilic syndrome (HES), a rare condition that can damage organs. About 70 adults and children (age 2 and up) with a specific form…
Matched conditions: HYPEREOSINOPHILIC SYNDROME
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC